EpiEndo

14/02/2022

In the January edition of the Nordic Life Science Magazine (www.nordiclifescience.org), the leading life science business magazine in the Nordics there is an article about us.
EpiEndo – a Nordic star on a Global mission! You can read the article here: https://www.e-magin.se/paper/nk57vq7z/paper/1 #/paper/nk57vq7z/1

11/01/2022

As a biology technician you will:
• Assist the Preclinical team to advance cellular models into standardized, reproducible, and medium or high throughput methodology that provide data in a standardized format that drive rapid development of new drugs
• Perform given tasks and bench activities with minimal supervision
• Be resourceful in finding resolutions to technical problems/issues
• Serve as a technical resource for other staff and contribute to multiple projects executed in parallel
• Share biology lab, equipment and cell bank maintenance responsibilities
• Have excellent oral and written communication skills in English
• Be familiar with scientific literature search tools
• Keep detailed experiment documentation (MS Office, electronic laboratory notebook)
• Be able to effectively communicate results with other scientists and present results during project team meetings
• Enjoy laboratory work

11/01/2022

As biologists you will:
• Design, execute and critically analyze in vitro studies to develop and characterize models for new indications.
• Transform advanced cellular models into standardized, reproducible, and medium or high throughput methodology that provide data in a standardized format that drives rapid development of new drugs
• Independently manage your workload, design and perform bench activities independently or with minimal supervision, able to drive novel research strategies and deliver to timelines
• Serve as an industry-experienced resource for other staff and leverage expertise in laboratory technology as a functional resource/trainer
• Share responsibilities for the biology lab, equipment and cell bank maintenance in a team environment within a shared facility
• Have excellent oral and written communication skills, including writing, reviewing and editing scientific documents in English
• Be able to effectively communicate results and drive thoughtful discussion during project team meetings
• Be familiar with scientific literature search and reference management tools
• Keep detailed data collection, organization, and experiment documentation (MS Office, electronic laboratory notebook)
• Enjoy laboratory work

13/12/2021

We are looking for a Director Clinical Operations at EpiEndo Pharmaceuticals, is that you?

EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, GI tract and skin. Our lead program EP395 is currently in Phase 1 but will expand into Phase 2 in 2022. We are therefo...

25/10/2021

EpiEndo Pharma wins the prestigious Swedish American Life Science Summit (SALSS) Rising Star Award 2021.

The SALSS Rising Star Award recognizes a life science company with the potential to revolutionize and influence a global market and was presented in Stockholm on Friday the 22nd of October to Maria Bech, CEO and Dr Fridrik Gardarsson, Founder and Chief Innovation Officer of EpiEndo, by Barbro Ehnbom, Founder and Chairman of SALSS.

The SALSS 2021 distinguished international panel of judges for the award comprised: Dr. Robert Langer, Koch Institute Professor, MIT and co-founder of Moderna, Dr. Mathias Uhlén, Professor, the Royal Institute of Technology (KTH) and multiple biotechnology entrepreneur, Dr. Mikael Dolsten, President, Worldwide Research & Development, Pfizer and Dr. Eugen Steiner, Venture Partner, Stockholm-based venture capital firm HealthCap. The panel assessed scientific and medical innovation, potential for healthcare impact, stage of commercial realization and environmental impact and concluded:

“The winner of SALSS 2021 Rising Stars is EpiEndo for its level of innovation and potential impact in COPD, one of the leading causes of debilitating disease and death globally. EpiEndo is developing a candidate drug with a novel mode of action that, if successfully brought to the patients, could change the treatment paradigm for COPD. EpiEndo won the top scores from all judges in the criteria of level of scientific and medical innovation and potential for healthcare impact, giving it the lead over competitors.”

EpiEndo Pharma receives the Swedish American Life Science Summit (SALSS) Rising Star Award 2021 for its innovation and potential impact in COPD

18/08/2021

EpiEndo Pharmaceuticals has secured funding of EUR 20 million, equivalent to almost ISK 3 billion, to continue clinical trials of a drug that could become the first Icelandic original drug.

Hlutafjáraukning upp á 3 milljarða króna, meðal annars frá sjóði í eigu stofnanda lyfjarisans Recipharm, gerir íslenska líftæknifyrirtækinu EpiEndo kleift að þróa áfram frumlyf.

18/08/2021

EpiEndo Secures €20 Million Series A Funding

“I am delighted to announce the closing of this new investment round,” commented Maria Bech, CEO of EpiEndo Pharma. “We are very pleased to welcome such well-reputed investors as Flerie Invest and Iðunn Venture Fund to help us build our company and are honoured that the European Innovation Council Fund has chosen EpiEndo as its first follow-on investment. We are also grateful for the continued support of our existing investors. This financing is a major step for EpiEndo, not only funding our lead compound through clinical development in patients with COPD, but also enabling exploration of other important potential therapeutic application areas such as dermatology and gastrointestinal disorders, where compromised epithelial integrity is known to contribute to disease pathophysiology.”

EpiEndo Pharmaceuticals Secures €20M Series A Funding to Advance Clinical Development of its Lead Compound EP395 for the Treatment of COPD.

28/05/2021

EPIENDO PHARMA Wins #1 Place in Biotech & Pharmaceuticals, at the European Innovation Council Investor Day on Health 2021

The EIC Investor Day on Health, which took place on 18-19 May 2021, focused on innovations in the field of biotech, pharmaceuticals, medtech and ehealth. In total 25 EIC beneficiaries had the opportunity to pitch in front of 17 top-tier investors in the health-sector.

The EIC Investor Day on Health, which took place on 18-19 May 2021, focused on innovations in the field of biotech, pharmaceuticals, medtech and ehealth. In total 25 EIC beneficiaries had the opportunity to pitch in front of 17 top-tier investors in the health-sector.  

15/04/2021

EpiEndo Pharmaceuticals ehf. tryggði sér nýverið 2,7 milljón evru fjármögnun í formi breytanlegs láns frá The European Innovation Council Fund (EIC Fund). Greint er frá þessu í fréttatilkynningu þar sem segir að fjármagnið muni styðja við klínískar rannsóknir og áframhaldandi vöxt félagsins næstu misserin.

EpiEndo Pharmaceuticals ehf. tryggði sér nýverið 2,7 milljón evru fjármögnun í formi breytanlegs láns frá The European Innovation Council Fund (EIC Fund). Greint er frá þessu í fréttatilkynningu þar sem segir að fjármagnið muni styðja við klínískar rannsóknir og áframhaldandi...

15/04/2021

EpiEndo Announces €2.7 million Investment by the European Innovation Council (EIC) Fund

REYKJAVIK, ICELAND – 15 April 2021 – EpiEndo announced today that it is the recipient of a €2.7 million convertible loan from the European Innovation Council (EIC) Fund. The Fund, created by the European Commission in 2020, aims to provide direct equity investments in breakthrough innovation companies and offer the opportunity for other private investors to co-fund such highly innovative companies.

READ MORE:

EpiEndo Pharma is the recipient of a €2.7 million convertible loan from the European Innovation Council (EIC) Fund.

13/04/2021

EpiEndo Pharmaceuticals announced today that the first subjects have been dosed in the Company's first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK. The trial is led by Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester and Medical Director at MEU.

"I am delighted to say that our single ascending dose study has started and that the first six healthy subjects have been given a dose of EP395,” commented Dr. Ginny Norris, EpiEndo’s Chief Medical Officer, “The study will now continue with further single dosing and, later, multiple dosing. Dosing of our first subjects with EP395 is an important milestone for EpiEndo, as it brings us one step closer to offering a potentially meaningful therapeutic option to patients with COPD. This study will produce important early clinical data to guide our future development plans and continues to demonstrate EpiEndo’s leadership in development of non-antibiotic macrolides.”

FULL RELEASE:

EpiEndo Pharma Announces First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases

07/04/2021

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board of Directors.

“On behalf of all of our colleagues I’d like to extend a very warm welcome to both Sigríður and Robert,” commented Prof Clive Page, OBE, Chairman of EpiEndo’s Board of Directors, “Their expertise across entrepreneurship, finance and the pharmaceutical industry is a perfect complement and brings a wealth of additional experience to the Board. I would also like to convey our gratitude for his years of service and thank EpiEndo’s Founder, Dr. Friðrik Garðarsson for his leadership, as he steps away from the Board to focus on the key executive role of Chief Innovation Officer of the Company, spearheading our strategic development. We are also immensely grateful to Prof Olafur Baldursson, whose field-leading science discoveries were a basis for EpiEndo’s inception. He will also be stepping down from his role on the Board but continues his active involvement with EpiEndo as an expert member of our Scientific Advisory Board.”

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board